Stephens Consulting, LLC Novavax Inc Transaction History

Stephens Consulting, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 19, 2023	SELL	$5.76 - $12.48 $11 - $24	-2 Reduced 0.2%	1,000 $6.93 Million
Q3 2022 Jan 19, 2023	SELL	$18.2 - $76.12 $18,200 - $76,120	-1,000 Reduced 49.95%	1,002 $18.2 Million
Q2 2022 Jan 19, 2023	SELL	$36.28 - $75.29 $362 - $752	-10 Reduced 0.5%	2,002 $103 Million
Q1 2022 Jan 19, 2023	SELL	$69.73 - $142.9 $139,460 - $285,800	-2,000 Reduced 49.85%	2,012 $148 Million
Q4 2021 Jan 19, 2023	BUY	$134.56 - $217.97 $539,854 - $874,495	4,012 New	4,012 $574 Million

284

93.7M

5.4M

8.76M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $568M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Stephens Consulting, LLC, based on Form 13F filings with the SEC.

Stay updated on Stephens Consulting, LLC with notifications on news.